Some studies have shown that tumor mutational burden (TMB), programmed death receptor ligand-1 (PD-L1), and microsatellite instability (MSI) are effective biomarkers for assessing the efficacy of immune checkpoint inhibitors (ICIs) [2]. This evidence concerns the gene CD274 and neoplasm.